CD274 and non-small cell lung carcinoma: Waterhouse et al. reported a median OS of 19.1 months for combination therapy and 15.3 months for monotherapy for NSQ NSCLC with PD-L1 ≥50%, while the numbers were 12.3 versus 11.9 months for SQ NSCLC [13].